CCL17 and Alzheimer disease: One of the most promising biomarkers appears to be the thymus and activation-regulated chemokine/C-C motif ligand 17 (TARC/CCL17), which correlates with AD severity in children and adults and has been used in Japan in clinical practice since 2008 [23].